Your search returned 12 results.

Results
	1.	Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. [electronic resource] by Hajdenberg, Julio Grote, Thomas Yee, Lorrin Arevalo-Araujo, Roberto Latimer, Laurie A Producer: 20070216 In: The journal of supportive oncology vol. 4 Availability: No items available. Save to lists Add to cart (remove)
	2.	Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. [electronic resource] by Senecal, Frank M Yee, Lorrin Gabrail, Nashat Charu, Veena Tomita, Dianne Rossi, Greg Schwartzberg, Lee Producer: 20060126 In: Clinical breast cancer vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. [electronic resource] by Schwartzberg, Lee Burkes, Ronald Mirtsching, Barry Rearden, Timothy Silberstein, Peter Yee, Lorrin Inamoto, Amy Lillie, Tom Producer: 20110321 In: BMC cancer vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. [electronic resource] by Schwartzberg, Lee S Yee, Lorrin K Senecal, Frank M Charu, Veena Tomita, Dianne Wallace, Joel Rossi, Greg Producer: 20050322 In: The oncologist vol. 9 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. [electronic resource] by Quinn, David I Nemunaitis, John Fuloria, Jyotsna Britten, Carolyn D Gabrail, Nashat Yee, Lorrin Acharya, Milin Chan, Kai Cohen, Nadine Dudov, Assen Producer: 20090710 In: Clinical pharmacokinetics vol. 48 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. [electronic resource] by Brana, Irene Calles, Antonio LoRusso, Patricia M Yee, Lorrin K Puchalski, Thomas A Seetharam, Shobha Zhong, Bob de Boer, Carla J Tabernero, Josep Calvo, Emiliano Producer: 20151209 In: Targeted oncology vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. [electronic resource] by Rosen, Peter J Sweeney, Christopher J Park, Dorothy J Beaupre, Darrin M Deng, Hongjie Leitch, Ian M Shubhakar, Poornima Zhu, Min Oliner, Kelly S Anderson, Abraham Yee, Lorrin K Producer: 20100820 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. [electronic resource] by Fuchs, Charles S Fakih, Marwan Schwartzberg, Lee Cohn, Allen L Yee, Lorrin Dreisbach, Luke Kozloff, Mark F Hei, Yong-jiang Galimi, Francesco Pan, Yang Haddad, Vincent Hsu, Cheng-Pang Sabin, Antony Saltz, Leonard Producer: 20140416 In: Cancer vol. 119 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors. [electronic resource] by LoRusso, Patricia Jänne, Pasi A Oliveira, Moacyr Rizvi, Naiyer Malburg, Lisa Keedy, Vicki Yee, Lorrin Copigneaux, Catherine Hettmann, Thore Wu, Chi-Yuan Ang, Agnes Halim, Abdel-Baset Beckman, Robert A Beaupre, Darrin Berlin, Jordan Producer: 20140108 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. [electronic resource] by Calvo, Emiliano Azaro, Analia Rodon, Jordi Dirix, Luc Huizing, Manon Senecal, Francis Mark LoRusso, Patricia Yee, Lorrin Poggesi, Italo de Jong, Jan Triantos, Spyros Park, Youn C Knoblauch, Roland E Parekh, Trilok V Demetri, George D von Mehren, Margaret Producer: 20190225 In: Investigational new drugs vol. 36 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. [electronic resource] by Mita, Monica M Spear, Matthew A Yee, Lorrin K Mita, Alain C Heath, Elisabeth I Papadopoulos, Kyriakos P Federico, Kristine C Reich, Steven D Romero, Ofelia Malburg, Lisa Pilat, MaryJo Lloyd, G Kenneth Neuteboom, Saskia T C Cropp, Gillian Ashton, Edward LoRusso, Patricia M Producer: 20110331 In: Clinical cancer research : an official journal of the American Association for Cancer Research vol. 16 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. [electronic resource] by Hesketh, Paul J Arena, Francis Patel, Dhimant Austin, Matt D'Avirro, Paul Rossi, Gregory Colowick, Alan Schwartzberg, Lee Bertoli, Luigi F Cole, John T Demetri, George Dessypris, Emmanuel Dobbs, Tracy Eisenberg, Peter Fleischman, Roger Hall, James Hoffman, Phillip C Laber, Damian A Leonard, John Lester, Eric P McCachren, Spence McMeekin, Scott Meza, Luis Miller, David Scott Nand, Sucha Oliff, Ira Paroly, Warren Pawl, Larry Perez, Alejandra Raftopoulos, Harry Rigas, James Rowland, Kendrith Scullin, Daniel C Tezcan, Haluk Waples, John Ward, John Yee, Lorrin K Producer: 20040309 In: Cancer vol. 100 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)